Myeloid Metaplasia – Pipeline Review, H2 2011

Myeloid Metaplasia – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Myeloid Metaplasia - Pipeline Review, H2 2011', provides an overview of the Myeloid Metaplasia therapeutic pipeline. This report provides information on the therapeutic development for Myeloid Metaplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloid Metaplasia. 'Myeloid Metaplasia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Myeloid Metaplasia.
• A review of the Myeloid Metaplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Myeloid Metaplasia pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Myeloid Metaplasia.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Myeloid Metaplasia pipeline depth and focus of Myeloid Metaplasia therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Myeloid Metaplasia Overview
Therapeutics Development
An Overview of Pipeline Products for Myeloid Metaplasia
Myeloid Metaplasia Therapeutics under Development by Companies
Myeloid Metaplasia Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Myeloid Metaplasia Therapeutics – Products under Development by Companies
Myeloid Metaplasia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Myeloid Metaplasia Therapeutics Development
Novartis AG
Celgene Corporation
Myeloid Metaplasia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Afinitor - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BMS-354825 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
R115777 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Actimid + Prednisone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Thalidomide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pegasys - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Zometa - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gleevec - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cyclophosphamide + Prednisone + Thalidomide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Myeloid Metaplasia Therapeutics – Drug Profile Updates
Myeloid Metaplasia Therapeutics – Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Myeloid Metaplasia, H2 2011
Products under Development for Myeloid Metaplasia – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Novartis AG, H2 2011
Celgene Corporation, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Myeloid Metaplasia Therapeutics – Drug Profile Updates
Myeloid Metaplasia Therapeutics – Discontinued Products

LIST OF FIGURES

Number of Products under Development for Myeloid Metaplasia, H2 2011
Products under Development for Myeloid Metaplasia – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mid Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top